Literature DB >> 33456904

Anaesthesia for retroperitoneal lymph node dissection in the treatment of testicular cancer.

M Stephens1, T Murphy2, D Hendry2.   

Abstract

Entities:  

Year:  2019        PMID： 33456904      PMCID： PMC7808039          DOI： 10.1016/j.bjae.2019.04.003

Source DB:  PubMed          Journal:  BJA Educ        ISSN： 2058-5349


× No keyword cloud information.
  19 in total

1.  Long-term survival after treatment with gemcitabine and oxaliplatin with and without paclitaxel plus secondary surgery in patients with cisplatin-refractory and/or multiply relapsed germ cell tumors.

Authors:  Karin Oechsle; Christian Kollmannsberger; Friedemann Honecker; Frank Mayer; Cornelius F Waller; Jörg T Hartmann; Ina Boehlke; Carsten Bokemeyer
Journal:  Eur Urol       Date:  2011-06-24       Impact factor: 20.096

2.  Bleomycin-induced pulmonary fibrosis in fibrinogen-null mice.

Authors:  N Hattori; J L Degen; T H Sisson; H Liu; B B Moore; R G Pandrangi; R H Simon; A F Drew
Journal:  J Clin Invest       Date:  2000-12       Impact factor: 14.808

3.  Outcome analysis for patients with elevated serum tumor markers at postchemotherapy retroperitoneal lymph node dissection.

Authors:  Stephen D W Beck; Richard S Foster; Richard Bihrle; Lawrence H Einhorn; John P Donohue
Journal:  J Clin Oncol       Date:  2005-09-01       Impact factor: 44.544

4.  Factors influencing postoperative morbidity and mortality in patients treated with bleomycin.

Authors:  P L Goldiner; G C Carlon; E Cvitkovic; O Schweizer; W S Howland
Journal:  Br Med J       Date:  1978-06-24

5.  Restrictive versus Liberal Fluid Therapy for Major Abdominal Surgery.

Authors:  Paul S Myles; Rinaldo Bellomo; Tomas Corcoran; Andrew Forbes; Philip Peyton; David Story; Chris Christophi; Kate Leslie; Shay McGuinness; Rachael Parke; Jonathan Serpell; Matthew T V Chan; Thomas Painter; Stuart McCluskey; Gary Minto; Sophie Wallace
Journal:  N Engl J Med       Date:  2018-05-09       Impact factor: 91.245

6.  A randomized phase III study of 72 h infusional versus bolus bleomycin in BEP (bleomycin, etoposide and cisplatin) chemotherapy to treat IGCCCG good prognosis metastatic germ cell tumours (TE-3).

Authors:  J Shamash; S-J Sarker; R Huddart; S Harland; J K Joffe; D Mazhar; A Birtle; J White; K Chowdhury; P Wilson; M R Marshall; S Vinnicombe
Journal:  Ann Oncol       Date:  2017-06-01       Impact factor: 32.976

7.  Perioperative fluid therapy: a statement from the international Fluid Optimization Group.

Authors:  Lais Helena Camacho Navarro; Joshua A Bloomstone; Jose Otavio Costa Auler; Maxime Cannesson; Giorgio Della Rocca; Tong J Gan; Michael Kinsky; Sheldon Magder; Timothy E Miller; Monty Mythen; Azriel Perel; Daniel A Reuter; Michael R Pinsky; George C Kramer
Journal:  Perioper Med (Lond)       Date:  2015-04-10

8.  Safety and efficacy of resistance training in germ cell cancer patients undergoing chemotherapy: a randomized controlled trial.

Authors:  J F Christensen; L W Jones; A Tolver; L W Jørgensen; J L Andersen; L Adamsen; P Højman; R H Nielsen; M Rørth; G Daugaard
Journal:  Br J Cancer       Date:  2014-05-27       Impact factor: 7.640

9.  Pre-treatment clinical assessment in head and neck cancer: United Kingdom National Multidisciplinary Guidelines.

Authors:  A Robson; J Sturman; P Williamson; P Conboy; S Penney; H Wood
Journal:  J Laryngol Otol       Date:  2016-05       Impact factor: 1.469

Review 10.  Vascular Complications of Cancer Chemotherapy.

Authors:  Alan C Cameron; Rhian M Touyz; Ninian N Lang
Journal:  Can J Cardiol       Date:  2015-12-28       Impact factor: 5.223
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.